top of page
  • D. Brit

FDA Panel Supports Pfizer's Low-Dose Covid-19 Vaccine For Kids Ages 5-11

What Happened:

  • On Tuesday, a Food and Drug Administration advisory panel voted that the benefits of Pfizer's low-dose Covid-19 vaccine for kids ages 5-11 far outweigh the potential risks.

  • Last Friday, Pfizer released a study showing that their Covid-19 vaccine proved to be nearly 91% effective at preventing symptomatic infections in kids ages 5-11.

  • If regulators approve the vaccine, the rollout could begin as soon as early November.

  • Pfizer requested vaccine authorization for this age group a few weeks back. The FDA and CDC are expected to make a final decision next week.

  • Pfizer tested smaller doses in the young children, a third of what's normally given to adults and teens. The trials proved to be effective with the young children developing antibodies against Covid-19 and having minimal side effects.

Photo Source: WIX Media

#newspura #justfactsnoopinions #covid19 #coronavirus #news #breakingnews #breaking #vaccines #pfizer #biontech #deltavariant #childvaccines

12 views0 comments
bottom of page